Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06387667
NA

Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections

Sponsor: New Valley University

View on ClinicalTrials.gov

Summary

Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance.

Official title: Unveiling the Fungal Frontier: Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

250

Start Date

2025-12-01

Completion Date

2027-06-01

Last Updated

2025-08-14

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

Complete blood count

blood sample

DIAGNOSTIC_TEST

C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)

serum sample

RADIATION

CT chest

Computed tomography of the chest

DIAGNOSTIC_TEST

Microscopic examination

sputum and bronchoalveolar lavage (BAL)

DIAGNOSTIC_TEST

culture and sensitivity

for bacterial and fungal